Trade

with

Enzon Pharmaceuticals Inc
(NASDAQ: ENZN)
AdChoices
1.01
-0.01
-0.98%
After Hours :
1.02
+0.01
+0.99%

Open

1.08

Previous Close

1.02

Volume (Avg)

215.20k (532.61k)

Day's Range

0.9900-1.08

52Wk Range

0.7800-1.83

Market Cap.

45.01M

Dividend Rate ( Yield )

-

Beta

1.24

Shares Outstanding

44.13M

P/E Ratio (EPS)

1.70 (0.60)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 34.49M

    • Net Income

    • 18.15M

    • Market Cap.

    • 45.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 80.15

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.24

    • Forward P/E

    • -

    • Price/Sales

    • 1.35

    • Price/Book Value

    • 2.16

    • Price/Cash flow

    • 1.68

      • EBITDA

      • 20.48M

      • Return on Capital %

      • 137.19

      • Return on Equity %

      • 152.47

      • Return on Assets %

      • 137.19

      • Book Value/Share

      • 0.47

      • Shares Outstanding

      • 44.13M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -3.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • 45.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -29.42

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 79.58

            • 39.38

            • Net Profit Margin

            • 80.15

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 94.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -2.10

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 36.90

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 27.51

              • 2.92

              • Quick Ratio

              • 26.98

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 0.47

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 1.62

                • 243.90

                • P/E Ratio 5-Year High

                • 21.18

                • 634.30

                • P/E Ratio 5-Year Low

                • 1.30

                • 124.82

                • Price/Sales Ratio

                • 1.30

                • 9.29

                • Price/Book Value

                • 2.08

                • 8.39

                • Price/Cash Flow Ratio

                • 1.68

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 152.47

                    (25.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 137.19

                    (11.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 152.47

                    (13.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 26.44M

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 1.71

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  18.16M
                  Operating Margin
                  52.65
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  1.68
                  Ownership

                  Institutional Ownership

                  63.40%

                  Top 10 Institutions

                  45.50%

                  Mutual Fund Ownership

                  11.09%

                  Float

                  74.84%

                  5% / Insider Ownership

                  5.53%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Small Cap Growth Equity Port

                  •  

                    631,173

                  • 0.00

                  • 1.43

                  • Vanguard Extended Market Index Fund

                  •  

                    568,990

                  • 0.51

                  • 1.29

                  • Vanguard Total Stock Mkt Idx

                  •  

                    538,301

                  • 0.00

                  • 1.22

                  • Brandes Global Small Cap Equity Fund

                  •  

                    390,390

                  • 0.00

                  • 0.89

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    301,457

                  • 0.00

                  • 0.68

                  • PowerShares FTSE RAFI US 1500 Sm-Md Port

                  •  

                    297,347

                  • 0.49

                  • 0.64

                  • Nationwide Bailard Cognitive Value Fund

                  •  

                    281,121

                  • -15.72

                  • 0.64

                  • DFA U.S. Small Cap Portfolio

                  •  

                    213,649

                  • 0.00

                  • 0.48

                  • Goldman Sachs Global Small Cap Core

                  •  

                    188,922

                  • 0.00

                  • 0.43

                  • BlackRock Master Small Cap Growth Port

                  •  

                    153,792

                  • 0.00

                  • 0.35

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Icahn Associates Corp

                  •  

                    5,904,863

                  • 0.00%

                  • 13.38

                  • BlackRock Fund Advisors

                  •  

                    3,138,340

                  • -9.44%

                  • 7.11

                  • Vanguard Group, Inc.

                  •  

                    1,247,815

                  • -3.60%

                  • 2.83

                  • Dimensional Fund Advisors, Inc.

                  •  

                    1,149,255

                  • -5.70%

                  • 2.60

                  • Renaissance Technologies Corp

                  •  

                    1,118,184

                  • +15.04%

                  • 2.53

                  • Brandes Investment Partners & Co.

                  •  

                    1,043,363

                  • -0.48%

                  • 2.36

                  • BlackRock Advisors LLC

                  •  

                    818,410

                  • -2.62%

                  • 1.85

                  • Price Michael F

                  •  

                    748,200

                  • 0.00%

                  • 1.70

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Value

                  Enzon Pharmaceuticals Inc is a biotechnology company. The Company is related to sales of six marketed drug products namely, PegIntron, Sylatron, Macugen, CIMZIA, Oncaspar and Adagen. The Company generates revenues from the royalty from the sales of PegIntron marketed by Merck & Co., Inc. The Company has a strategic alliance with Zhejiang Hisun Pharmaceuticals Co. Ltd development and commercialization rights for PEG-SN38 in China.

                  Key People

                  Mr. George W. Hebard, III

                  CEO/COO/Secretary

                  Mr. Jonathan Christodoro

                  Director/Chairman of the Board

                  Mr. Richard L. Feinstein

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Dr. Odysseas D. Kostas

                  Director

                  Ms. Jennifer McNealey

                  Director

                  • Enzon Pharmaceuticals Inc

                  • 20 Kingsbridge Road

                  • Piscataway, NJ 08854

                  • USA.Map

                  • Phone: +1 732 980-4500

                  • Fax: +1 908 575-9457

                  • enzon.com

                  Incorporated

                  0

                  Employees

                  1

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: